Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 17/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134594 | 0.83 | HSD17B10 (0.51) | POLBKIF11 | |
| SCHEMBL4839082 | 0.83 | KIF11 (0.43) | KIF11DNMT1 | |
| SCHEMBL31676108 | 0.82 | HSD17B10 (0.47) | KIF11 | |
| SCHEMBL4158244 | 0.82 | KDM4E (0.50) | POLBKIF11DNMT1 | |
| SCHEMBL4831433 | 0.81 | CYP1A2 (0.48) | KIF11 | |
| SCHEMBL4839273 | 0.81 | CYP1A2 (0.48) | KIF11 | |
| SCHEMBL4840293 | 0.79 | KIF11 (0.43) | KIF11DNMT1 | |
| SCHEMBL4838957 | 0.78 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL4840669 | 0.76 | KIF11 (0.43) | KIF11DNMT1 | |
| SCHEMBL4831186 | 0.76 | SRR (0.51) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1200131-A2 | COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS | Marker Gene Technologies, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001002020-A2 | COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS | MARKER GENE TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | POLB 4497/4885KIF11 3755/4885HTT 4665/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | POLB 4603/4885KIF11 4388/4885HTT 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.